Ideaya Biosciences Inc IDYA

NAS: IDYA | ISIN: US45166A1025   30/04/2025
20,13 USD (+2,18%)
(+2,18%)   30/04/2025

28 april 2025 · IDEAYA Biosciences to Participate in Upcoming May 2025 Investor Relations Events · Persbericht

25 april 2025 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

14 april 2025 · IDEAYA Biosciences Announces Successful FDA Type D Meeting on Phase 3 Registrational Trial Design for Darovasertib as Neoadjuvant Therapy for Primary Uveal Melanoma · Persbericht

10 april 2025 · IDEAYA Biosciences Announces Phase 1/2 Expansion for IDE397 and Trodelvy® Combination in MTAP-Deletion Urothelial Cancer · Persbericht

1 april 2025 · IDEAYA Biosciences Announces Participation in Upcoming April 2025 Investor Relations Events · Persbericht

31 maart 2025 · IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma · Persbericht

28 maart 2025 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

26 maart 2025 · IDEAYA Announces Oral Presentation at the New Drugs on the Horizon Series at AACR 2025 for IDE275 (GSK959), a Phase 1 Werner Helicase Inhibitor · Persbericht

3 maart 2025 · IDEAYA Biosciences Announces Collaboration with ATTMOS to Accelerate AI/ML-Enabled Drug Discovery for Unprecedented First-in-Class Oncology Targets · Persbericht

30 augustus 2024 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

26 augustus 2024 · IDEAYA Biosciences to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference · Persbericht

23 augustus 2024 · IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) · Persbericht

6 augustus 2024 · IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update · Persbericht

31 juli 2024 · IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen · Persbericht

29 juli 2024 · IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event · Persbericht

11 juli 2024 · IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

10 juli 2024 · IDEAYA Announces Pricing of Public Offering · Persbericht

9 juli 2024 · IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants · Persbericht

8 juli 2024 · IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer · Persbericht

5 juli 2024 · IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024 · Persbericht

Mijn selecties